Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
-
Published:2021-06-18
Issue:13
Volume:48
Page:4437-4444
-
ISSN:1619-7070
-
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
-
language:en
-
Short-container-title:Eur J Nucl Med Mol Imaging
Author:
Klain Michele, Nappi Carmela, Zampella Emilia, Cantoni Valeria, Green Roberta, Piscopo Leandra, Volpe Fabio, Manganelli Mariarosaria, Caiazzo Elisa, Petretta Mario, Schlumberger Martin, Cuocolo AlbertoORCID
Abstract
Abstract
Purpose
We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence.
Methods
A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement.
Results
The final analysis included 9 studies accounting for 3103 patients at intermediate-high risk of recurrence. In these patients, the successful ablation rates ranged from 51 to 94% with a 71% pooled successful ablation and were higher in intermediate (72%) than in high (52%)-risk patients. Despite the rigorous inclusion standards, a significant heterogeneity among the evaluated studies was observed. Higher administered RAI activities are associated with a lower successful ablation rate in the whole population and in the subgroup of high-risk patients. Furthermore, pooled recurrence rate in intermediate-risk patients achieving successful ablation was only 2% during the subsequent 6.4-year follow-up while the pooled recurrence rate was 14% in patients who did not achieve a successful ablation.
Conclusion
In a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control.
Funder
Università degli Studi di Napoli Federico II
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference30 articles.
1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. 2. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9. 3. Orosco RK, Hussain T, Noel JE, Chang DC, Dosiou C, Mittra E, et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr Relat Cancer. 2019;26:795–802. 4. Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S479–85. 5. Tuttle M, Morris LF, Haugen B, Shah J, Sosa JA, Rohren E, et al. Thyroid differentiated and anaplastic carcinoma. In: Amin MB, Edge SB, Greene F, Byrd D, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley J, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. Eighth ed. New York: Springer International Publishing; 2017.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|